Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.
Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide (Pomalyst) in multiple myeloma.
First, in the phase III randomized OPTIMISMM trial, the 3-drug regimen of pomalidomide with bortezomib (Velcade) and dexamethasone (PVd) was compared to the combination of bortezomib/dexamethasone. An 11-month progression-free survival (PFS) was found with the triplet regimen, versus 7.9 months in the control arm, according to Lonial.
These results are significant for these patients with early relapse. Lonial also notes that in the first patients to relapse, the PFS was at almost 20 months for the triplet regimen.
In the ELOQUENT-3 trial, patients with multiple myeloma were treated with either the triplet combination of elotuzumab (Empliciti) with pomalidomide and dexamethasone or pomalidomide/dexamethasone. The addition of elotuzumab improved PFS from about 3 months to over 10 months.
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
March 26th 2024During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Read More
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Read More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More